Table 1.
Patients characteristics (n = 117). All patients had invasive ductal carcinoma
| Group |
|||||
|---|---|---|---|---|---|
| A | B | C | Total | p | |
| n | 60 | 27 | 30 | 117 | |
| Median age, years (range) | 57 (33–73) | 60 (34–76) | 54.5 (37–74) | 57 (33–78) | 0.72** |
| T stage, n (%) | |||||
| 2 | 11 (18.3) | 4 (14.8) | 7 (23.3) | 22 (18.8) | 0.78* |
| 3 | 44 (73.3) | 20 (74.1) | 22 (73.3) | 86 (73.5) | |
| 4 | 5 (8.3) | 3 (11.1) | 1 (3.3) | 9 (7.7) | |
| N stage, n (%) | |||||
| 1 | 35 (58.3) | 19 (70.4) | 22 (73.3) | 0.29* | |
| 2 | 25 (41.7) | 8 (29.6) | 8 (26.7) | ||
| Postmenopausal patients, n (%) | 48 (80.0) | 22 (81.5) | 23 (76.7) | 93 (79.5) | 0.895* |
| Hormone receptors status, n (%) | |||||
| ER+ and/or PR+ | 55 (76.7) | 25 (92.6) | 29 (96.7) | 109 (93.2) | 0.429* |
| ER– and PR– | 5 (8.3) | 2 (7.4) | 1 (3.3) | 8 (6.8) | |
| HER2neu status, n (%) | |||||
| + | 25 (41.7) | 10 (37.1) | 12 (40.0) | 47 (40.2) | 0.92 |
| − | 35 (58.3) | 17 (62.9) | 18 (60.0) | 70 (59.8) | |
| Ki67 status, n (%) | |||||
| < 12% | 42 (70) | 15 (55.6) | 22 (73.3) | 79 (67.5) | 0.31 |
| > 12% | 18 (30.0) | 12 (44.4) | 8 (26.7) | 38 (32.5) | |
ER = Estrogen receptor, PR = progesterone receptor, HER2neu = human epidermal growth factor receptor.
*
chi2 test;
**
Kruskall-Wallis test.